KRAS
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
Cell-type Specific Alteration of Dicer1 Accelerates Tumor Progression in Mouse Models of KRAS-driven Lung Adenocarcinoma
MicroRNAs (miRNAs) have been widely implicated in cancer initiation and progression, yet examination of the effects of global miRNA disruption on these processes has been limited. We developed novel genetically engineered mouse models of Kras-driven pulmonary adenocarcinoma (LUAD) with cell-type-specific disruption of miRNA biosynthesis via Dicer1 allele deletion, which exhibit significant differences in tumor progression rates and expected survival. Dicer1 is an RNase III enzyme that is...
ShallowBench: Benchmarking Generative Drug Design Models on Shallow-Pocket Targets
arXiv:2606.06717v1 Announce Type: new Abstract: While generative AI models have demonstrated remarkable success in structure-based drug design, they predominantly rely on deep binding pockets and struggle to sample effective ligands for challenging low-pocketability targets, such as the historically "undruggable" oncology targets KRAS and MYC. To address this gap, we introduce ShallowBench, a strictly curated benchmark of 5,780 shallow-pocket targets extracted from CrossDocked2020.
Daily pill can double survival time for deadliest cancer, trial shows
A daily pill can double survival time in patients with the world’s deadliest cancer, according to the results of a clinical trial that experts are saying is a “gamechanger” and one of the biggest breakthroughs in decades. Currently, there are few treatments for pancreatic cancer, and most do little or nothing to help. For decades, scientists have worked relentlessly trying to find clever solutions for a form of cancer that is often found late.
Radiosensitization of Glioblastoma by the K-ras Inhibitor RMC-6236
Purpose: Glioblastoma (GBM) is characterized by poor clinical outcomes and marked resistance to radiotherapy. Because effective radiosensitizing strategies for GBM remain limited, we investigated whether inhibition of KRAS/RAS signaling could enhance radiation response in GBM. In particular, we evaluated the radiosensitizing potential of RMC-6236, an RAS(ON) multiselective inhibitor that suppresses active RAS signaling across multiple RAS-dependent states.
Scientists finally crack an “undruggable” pancreatic cancer target and nearly double survival
Scientists finally crack an “undruggable” pancreatic cancer target and nearly double survival A once-“undruggable” pancreatic cancer target has finally been cracked, and the new treatment nearly doubled survival in a landmark trial. - Date: - June 4, 2026 - Source: - The Conversation - Summary: -
Cancer breakthrough as new 'game-changing' pill could DOUBLE survival time for most deadly diseases
Cancer breakthrough as new 'game-changing' pill could DOUBLE survival time for most deadly diseases Prostate cancer patients normally have a devastatingly short life expectancy - but the new daily pill being offered in clinical trials could change that A “game-changing” daily pill helped almost double survival time for patients with the most deadly major cancer. Pancreatic cancer patients on the drug lived for twice as long as those on chemotherapy. The pill’s success is thought to be the...
Novel synthetic biomolecule degrades disease-related proteins
Novel synthetic biomolecule degrades disease-related proteins Lisa Lock Scientific Editor Robert Egan Associate Editor Northwestern Medicine scientists have developed a novel synthetic biomolecular condensate that can degrade intracellular disease-causing proteins, providing a framework for new therapeutic approaches for a wide range of diseases, as detailed in a recent study published in Nature Communications. Shana Kelley, Ph.D., the Neena B. Schwartz Professor of Chemistry, Biomedical...
After new drug’s ‘unprecedented’ results for pancreatic cancer, doctors look at other uses
Every single patient with advanced pancreatic cancer who walked into Dr. Zev Wainberg’s office told him they would rather take an experimental medication than endure another round of chemotherapy. Wainberg, co-director of UCLA Health’s GI Oncology Program, was leading a clinical trial of a new drug called daraxonrasib. All the study participants previously had chemotherapy that was starting to fail.
Cancer is now a story of the good, the bad and the ugly – but also hope | Devi Sridhar
It’s natural to focus on breakthroughs, but there are many challenges in Britain and around the world. There is no magic bullet, but there’s room for optimismCancer causes nearly one in six deaths worldwide every year, some 10 million all told. That is a stunning number, but it also masks the reality that some cancers are more deadly than others.
'Transformative' pancreatic cancer drug doubles survival time
A daily pill doubles the survival time of people with pancreatic cancer, one of the most aggressive and difficult-to-treat forms of the condition, even after they have stopped responding to chemotherapy. What’s more, the convenient pill has fewer side effects than standard chemotherapy. “It’s a transformative treatment,” says Pilar Acedo at University College London, who wasn’t involved in the research.